secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001193125-24-219180
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ACR-368 endometrial cancer Phase 2: 62.5% ORR in OncoSignature+ patients; ACR-2316 IND cleared
--------------------------------------------------------------------------------

- Confirmed ORR of 62.5% (95% CI 30.4-86.5) in prospectively-selected OncoSignature+ endometrial cancer patients who progressed on anti-PD-1.
- Statistically significant segregation of responders vs OncoSignature- arm (p=0.009); all responding patients still on therapy; mDoR not yet reached (~6 months).
- Endometrial cancer anticipated as first potential accelerated approval opportunity for ACR-368.
- FDA cleared IND for ACR-2316 (dual WEE1/PKMYT1 inhibitor); clinical sites activated; first-in-human dosing expected Q4 2024.
- Cash of $220.4M (June 30, 2024) expected to fund operations into H2 2026; guidance reiterated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312524219180/0001193125-24-219180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312524219180/d355136d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-219180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer